OSCR Quantitative Stock Analysis

Validea's guru fundamental report indicates Oscar Health Inc (OSCR), a mid-cap growth stock in the Insurance (Accident & Health) sector, received a 55% rating from its Small-Cap Growth Investor model, based on Motley Fool's strategy. This score falls below the 80% threshold for 'some interest,' suggesting the company does not currently meet the strategy's criteria for a compelling growth investment. The analysis highlights significant fundamental weaknesses in areas such as profit margin, cash flow from operations, and sales growth, despite some strengths in relative strength and cash position.

Analysis

Oscar Health Inc (OSCR) receives a low rating of 55% from Validea's Small-Cap Growth Investor model, a score that falls significantly short of the 80% threshold indicating strategic interest. The analysis reveals substantial fundamental weaknesses, with the company failing on critical metrics including profit margin, sales, cash flow from operations, and year-over-year sales and EPS growth comparisons. Furthermore, the model flags concerns regarding valuation, as indicated by a 'FAIL' on "The Fool Ratio" (P/E to Growth), and a lack of insider holdings. While OSCR does pass on certain criteria, such as relative price strength, a stable level of outstanding shares, and management of accounts receivable, these strengths are overshadowed by the failures in core profitability and growth areas. The negative sentiment score of -0.45 for OSCR corroborates this assessment, suggesting that despite some positive market momentum ('Relative Strength' pass), the underlying financial health of the company does not meet the rigorous standards of this particular growth-focused investment strategy.

Key Decisions for Investors

• Given the numerous failures on core fundamental metrics like profit margin, sales growth, and cash flow, investors following a growth-oriented strategy should view OSCR with significant caution as it does not fit the ideal profile.
• The 'PASS' on relative strength juxtaposed with a 'FAIL' on most financial health indicators suggests the stock's price performance may be disconnected from its fundamentals, warranting a risk assessment of a potential momentum reversal.
• Investors should closely monitor for a turnaround in the specific failed metrics, particularly operating cash flow and profit margins, before considering the stock a viable growth investment.
• The failure on the P/E to Growth ratio test indicates that the current valuation may be high relative to its demonstrated growth, suggesting a detailed valuation analysis is prudent before initiating or adding to a position.